Summary of Findings Table ‐ AbobotulinumtoxinA 50U showed no clear difference in total adverse events compared with onabotulinumtoxinA 20U (moderate certainty).
It is very uncertain whether summary of Findings Table ‐ IncobotulinumtoxinA 24U changes major adverse events compared with onabotulinumtoxinA 24U (very low certainty).
It is very uncertain whether summary of Findings Table ‐ IncobotulinumtoxinA 24U changes total adverse events compared with onabotulinumtoxinA 24U (very low certainty).
Summary of Findings Table ‐ AbobotulinumtoxinA 50U showed no clear difference in major adverse events ‐ Any major adverse events (eyelid ptosis,… compared with onabotulinumtoxinA 20U (moderate certainty).
Summary of Findings Table ‐ OnabotulinumtoxinA 20U probably leads to higher major adverse events compared with placebo (moderate certainty).
Summary of Findings Table ‐ OnabotulinumtoxinA 20U showed no clear difference in total adverse events compared with placebo (low certainty).
Summary of Findings Table ‐ AbobotulinumtoxinA 50U may leads to higher total adverse events compared with placebo (low certainty).
Summary of Findings Table ‐ IncobotulinumtoxinA 20U showed no clear difference in total adverse events compared with placebo (low certainty).
Summary of Findings Table ‐ DaxibotulinumtoxinA 40U probably leads to higher total adverse events compared with placebo (moderate certainty).
Summary of Findings Table ‐ AbobotulinumtoxinA 50U showed no clear difference in major adverse events (eyelid ptosis, eyelid sensory disorder,… compared with placebo (moderate certainty).